COLL
COLLEGIUM PHARMACEUTICAL, INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$22.77
+1.74%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- $1.80
- Revenue estimate
- $218.0M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- $1.92
- EPS estimate
- $1.72
- Revenue actual
- $199.9M
- Revenue estimate
- $199.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -8.3%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $46
- PT range
- $43 – $49
- Analysts
- 5
4 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | $1.72 | $1.92 | Beat 11.63% | $199.9M |
| May 7, 2026 | $1.52 | $1.76 | Beat 15.79% | $193.5M |
| Feb 26, 2026 | $2.19 | $0.43 | Miss -80.49% | $205.4M |
| Nov 6, 2025 | $1.88 | $2.25 | Beat 19.68% | $209.4M |
| May 8, 2025 | $1.43 | $1.49 | Beat 4.20% | $177.8M |
| Feb 27, 2025 | $1.54 | $1.77 | Beat 14.94% | $181.9M |
| Nov 7, 2024 | $1.66 | $1.61 | Miss -3.01% | $159.3M |
| Aug 8, 2024 | $1.56 | $1.62 | Beat 3.85% | $145.3M |
| May 9, 2024 | $1.49 | $1.45 | Miss -2.68% | $144.9M |
| Feb 22, 2024 | $1.33 | $1.58 | Beat 18.80% | $149.7M |
| Aug 3, 2023 | $1.22 | $1.26 | Beat 3.28% | $135.5M |
| May 4, 2023 | $1.32 | $1.32 | In line | $144.8M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026